Rocio Garcia-Carbonero
Overview
Explore the profile of Rocio Garcia-Carbonero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
5180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Olmo-Garcia M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, et al.
Oncologist
. 2025 Feb;
30(2).
PMID: 39998905
Patients with advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) have impaired nutritional and physical performance due to the cancer pathophysiology and its treatment. The NUTRIGETNE study sought to characterize the nutritional status...
2.
Sobrero A, Dasari A, Aquino J, Lonardi S, Garcia-Carbonero R, Elez E, et al.
Eur J Cancer
. 2025 Feb;
218:115268.
PMID: 39952149
Introduction: Maintaining or improving health-related quality of life (HRQoL) is as important as extending survival in metastatic colorectal cancer. We report an HRQoL analysis from FRESCO-2 (NCT04322539). Methods: Patients were...
3.
Andre T, Elez E, Lenz H, Jensen L, Touchefeu Y, Van Cutsem E, et al.
Lancet
. 2025 Jan;
405(10476):383-395.
PMID: 39874977
Background: CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line...
4.
Gonzalez-Flores E, Garcia-Carbonero R, Elez E, Redondo-Cerezo E, Safont M, Garcia R
Clin Transl Oncol
. 2025 Jan;
PMID: 39821481
Males have a higher incidence and mortality rate from colorectal cancer (CRC) compared with females. This review examines the reasons for these differences, including risk factors, screening participation, interpretation of...
5.
Andre T, Elez E, Van Cutsem E, Jensen L, Bennouna J, Mendez G, et al.
N Engl J Med
. 2024 Nov;
391(21):2014-2026.
PMID: 39602630
Background: Patients with microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer have poor outcomes with standard chemotherapy with or without targeted therapies. Nivolumab plus ipilimumab has shown clinical benefit in...
6.
Sarno F, Tenorio J, Perea S, Medina L, Pazo-Cid R, Juez I, et al.
Clin Cancer Res
. 2024 Nov;
31(2):278-287.
PMID: 39540844
Purpose: Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options. We compared the efficacy of comprehensive precision medicine against that of the conventional treatment in PDAC. Patients And Methods: We report...
7.
Ligero M, Hernando J, Delgado E, Garcia-Ruiz A, Merino-Casabiel X, Ibrahim T, et al.
BJC Rep
. 2024 Nov;
1(1):9.
PMID: 39516643
Background: More accurate predictive biomarkers in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are needed. This study aims to investigate radiomics-based tumour phenotypes as a surrogate biomarker of the tumour vasculature...
8.
Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teule A, Grande E, et al.
Nat Commun
. 2024 Aug;
15(1):6753.
PMID: 39117670
The prognosis of patients with advanced high-grade (G3) digestive neuroendocrine neoplasms (NENs) is rather poor. The addition of immune checkpoint inhibition to platinum-based chemotherapy may improve survival. NICE-NEC (NCT03980925) is...
9.
Cervantes A, Tabernero J, Garcia-Carbonero R, Sastre J, Feliu J, Guillen-Ponce C, et al.
Future Oncol
. 2024 Jun;
20(20):1401-1413.
PMID: 38861286
To describe the evolution of regorafenib use, since its approval, in patients with previously treated metastatic colorectal cancer (mCRC) in routine clinical practice in Spain. We extracted patient characteristics, dosing,...
10.
Valladares-Ayerbes M, Safont M, Gonzalez Flores E, Garcia-Alfonso P, Aranda E, Munoz A, et al.
Clin Transl Oncol
. 2024 Apr;
26(10):2640-2651.
PMID: 38642257
Purpose: RAS (KRAS/NRAS) mutational status on a tumor biopsy is mandatory to guide the best treatment in metastatic colorectal cancer (mCRC). Determining the RAS mutational status by tumor-tissue biopsy is...